Dr. Tehrani is the President and Chief Executive Officer of Zymeworks and has been a member of the Board of Directors since the company’s inception in September 2003. He has been an integral part of Zymeworks corporate achievements including raising seed and angel financing and overseeing the company’s technical operations and patent filings. Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in Biochemistry from the University of Massachusetts and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a board director for various life sciences and biotechnology organizations including the Student Biotechnology Network, CQDM, LifeSciences British Columbia, MITACS Industrial Advisory Board, and BIOTECanada’s Industrial and Environmental Committee. He was a Council Member on British Columbia’s Premier’s Technology Council from 2016 to 2018 and is currently a member of the board of directors of Creatus Biosciences Inc.
Dr. Burak has more than 20 years of pharmaceutical research and development experience in both biotechnology and large pharmaceutical companies. Before joining Fusion, he was Vice President of Development at Theracos Inc., where he was responsible for all research, clinical development and manufacturing activities for a company developing drugs to treat Type 2 diabetes. Previous positions include Vice President of Preclinical and Early Clinical Development at Rib-X Pharmaceuticals, Inc., a venture-funded antibiotic company, and Director of Drug Metabolism and Pharmacokinetics at Guilford Pharmaceuticals, Inc. Dr. Burak’s experience has focused on integrating discovery and development processes to accelerate the identification and development of new therapeutic agents. He has submitted 14 Investigational New Drug Applications (INDs) and has developed two approved products across multiple therapeutic areas including oncology, cardiovascular, antibiotics, diseases of the central and peripheral nervous system, anesthesia/sedation, diabetes, and wound healing. Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BSc in Chemistry from Drexel University.
Dr. Shirley Wu is the Director of Advanced Pharmaceutics Laboratory at Leslie Dan Faculty of Pharmacy, University of Toronto. She has over 27 years of experience and expertise in developing innovative drug delivery systems and pharmaceutical formulations for unmet medical needs including cancer. She is a co-inventor of 14 issued and 6 pending patents worldwide.
Dr. Amini is an experienced entrepreneur with strong business leadership and is experienced in various aspects of business formation, operation, and management. He is a veterinary doctor with several years of clinical practice and is also a PhD in Pharmaceutics from University of Toronto. He possesses extensive experience in leading and managing teams and projects in this field. He co-founded QurCan Therapeutics (formerly known as Nanology Labs) in 2018 and has been successful in establishing strategic relations with leading healthcare organizations in Canada, as well as internationally. He is recipient of several prestigious international entrepreneurship awards., including LabCentral Ignite Golden Ticket, MaRS HealthKick.
QUICK LINKSHome
Technology
Contact
|
LOCATIONS |